Since 2014, personalized medicines, like cell and gene therapies, have accounted for more than 20% of FDA approvals each year. This burgeoning field represents a new class of therapeutics, developed using an individual’s molecular profile for a more targeted treatment.
As promising as this rapidly evolving field is, personalized medicines are expensive and complicated to develop. To ensure cell and gene therapies are brought to market successfully, pharma companies must address complexities within the clinical supply chain, which requires specialized solutions, industry expertise and a rigorous control process coupled with advanced technology.
Examine how the next generation of therapies is disrupting supply chain logistics and explores solutions for the complexities within cell and gene therapies.